Anzeige
Mehr »
Sonntag, 27.07.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JQ4G | ISIN: US03843E1047 | Ticker-Symbol:
NASDAQ
25.07.25 | 21:59
4,145 US-Dollar
-1,31 % -0,055
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
AQUESTIVE THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
AQUESTIVE THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur AQUESTIVE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiAquestive Therapeutics, Inc.: Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer538WARREN, N.J., July 22, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement...
► Artikel lesen
15.07.Aquestive Therapeutics, Inc. - 8-K, Current Report1
15.07.Aquestive schedules regulatory meetings for epinephrine film in Canada, EU2
15.07.Aquestive Therapeutics, Inc.: Aquestive Therapeutics Provides International Expansion Update for Anaphylm (epinephrine) Sublingual Film125New Drug Submission meeting scheduled with Health Canada for the third quarter of 2025Initial briefing book submitted for review to the European Medicines Agency WARREN, N.J., July 15, 2025 (GLOBE...
► Artikel lesen
AQUESTIVE THERAPEUTICS Aktie jetzt für 0€ handeln
07.07.Aquestive Therapeutics, Inc.: Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism1
25.06.Aquestive Therapeutics, Inc.: Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm (epinephrine) Sublingual Film at the CFAAR Food Allergy Summit4
17.06.Aquestive stock maintains buy rating as FDA accepts anaphylaxis drug8
16.06.Aquestive gains as allergy therapy undergoes FDA review4
11.06.Aquestive Therapeutics, Inc. - 8-K, Current Report2
02.06.Aquestive Therapeutics, Inc. - 8-K, Current Report1
02.06.Oppenheimer senkt Kursziel für Aquestive Therapeutics auf 7 US-Dollar7
02.06.Oppenheimer lowers Aquestive Therapeutics stock price target to $71
13.05.Raymond James maintains Outperform on AQST with $7 target3
13.05.Aquestive Therapeutics targets $44M-$50M revenue in 2025 as Anaphylm launch preparations accelerate3
12.05.Aquestive Q1 2025 slides reveal Anaphylm progress but weakening financials3
12.05.Aquestive Therapeutics, Inc. - 10-Q, Quarterly Report 1
12.05.Aquestive Therapeutics, Inc.: Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update325Submitted NDA for Anaphylm (epinephrine), the first and only oral sublingual film for patients with severe allergic reactions Advancing commercial readiness efforts with a planned Q1 2026 launch of...
► Artikel lesen
12.05.Aquestive Therapeutics, Inc. - 8-K, Current Report1
09.05.Uncovering Potential: Aquestive Therapeutics' Earnings Preview2
09.04.Aquestive Therapeutics, Inc.: Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium2
Weiter >>
36 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1